Slow acting symptomatic agents in the therapy of osteoarthritis
- Authors: Pogozheva E.Y.1, Amirdzhanova V.N1
-
Affiliations:
- V.A.Nasonova Research Institute of Rheumatology
- Issue: Vol 19, No 2 (2017)
- Pages: 152-156
- Section: Articles
- URL: https://journal-vniispk.ru/2075-1753/article/view/94752
- ID: 94752
Cite item
Full Text
Abstract
The article presents the definition of osteoarthritis (OA), the main manifestations of the disease, the problems of OA therapy, the algorithm for managing patients with OA, the importance of educational programs, the combination of pharmacological and non-pharmacological methods of treatment, and the approach to prescribing analgesic therapy. The use of slow-acting symptomatic agents with high safety, symptom-modifying and potential structural-modifying action is discussed. Data on the features of the mechanism of action, clinical efficacy and safety of chondroitin sulfate, glucosamine and their combination are presented. The data of clinical trials of the preparation Arthra® is presented, its effectiveness in relation to pain syndrome and joint function improvement in patients with OA is shown, the safety and tolerability of the drug are noted, as well as its ability to preserve the effect after the end of therapy.
Full Text
##article.viewOnOriginalSite##About the authors
E. Yu Pogozheva
V.A.Nasonova Research Institute of Rheumatologyканд. мед. наук, ФГБНУ «НИИ ревматологии им. В.А.Насоновой» 115522, Russian Federation, Moscow, Kashirskoe sh., d. 34a
V. N Amirdzhanova
V.A.Nasonova Research Institute of Rheumatology
Email: lifequality@yandex.ru
д-р мед. наук, ФГБНУ «НИИ ревматологии им. В.А.Насоновой» 115522, Russian Federation, Moscow, Kashirskoe sh., d. 34a
References
- Ревматология. Клинические рекомендации. Под ред. Е.Л.Насонова. М.: ГЭОТАР - Медиа, 2010; с. 326.
- Насонов Е.Л. Ревматология. Клинические рекомендации. М.: ГЭОТАР - Медиа, 2005; с. 264.
- Jordan K.M, Arden N.K, Doherty M et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145-55.
- Zhang W, Nuki G, Moskowitz R.W et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18: 476-99.
- Bruyеre O, Cooper C, Pelletier J-P et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally. A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2014; 44 (3): 253-63.
- Persiani S, Rotini R, Trisolino G et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis Cartilage 2007; 15 (7): 764-72.
- Persiani S, Roda E, Rovati L.C et al. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage 2005; 13 (12): 1041-9.
- Derfoul A, Miyoshi A.D, Freeman D.E, Tuan R.S. Glucosamine promotes chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation. Osteoarthritis Cartilage 2007; 15 (6): 646-55.
- Varghese S, Theprungsirikul P, Sahani S et al. Glucosamine modulates chondrocyte proliferation, matrix synthesis, and gene expression. Osteoarthritis Cartilage 2007; 15 (1): 59-68.
- Kim M.M, Mendis E, Rajapakse N, Kim S.K. Glucosamine sulfate promotes osteoblastic differentiation of MG-63 cells via anti - inflammatory effect. Bioorg Med Chem Lett 2007; 17 (7): 1938-42.
- Mendis E, Kim M.M, Rajapakse N, Kim S.K. Sulfated glucosamine inhibits oxidation of biomolecules in cells via a mechanism involving intracellular free radical scavenging. Eur J Pharmacol 2008; 579 (1-3): 74-85.
- Mc Alindon T.E, La Valley M.P, Gulin J.P, Felson D.T. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta - analysis. JAMA 2000; 283 (11): 1469-75.
- Richy F, Bruyere O, Ethgen O et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta - analysis. Arch Intern Med 2003; 163 (13): 1514-22.
- Towheed T.E, Maxwell L, Anastassiades T.P et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005 (2): CD002946.
- Poolsup N, Suthisisang C, Channark P, Kittikulsuth W. Glucosamine long - term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. Ann Pharmacother 2005; 39 (6): 1080-7.
- Bruyere O, Pavelka K, Rovati L.C et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo - controlled trials. Osteoarthritis Cartilage 2008; 16 (2): 254-60.
- Volpi N. Therapeutic applications of glycosaminoglycans. Curr Med Chem 2006; 13 (15): 1799-810.
- Leeb B.F, Schweitzer H, Montag K et al. A Metaanalysis of Chondroitin Sulphate in the Treatment of Osteoarthritis. J Rheum 2000; 27: 205-11.
- Uebelhart D, Malaise V, Marcolongo R et al. Intermittent treatment of knee osteoarthritis with oral chondriitin sulfate: a one - year, randomized, double - blind, multicenter study versus placebo. Osteoarthritis Cartilage 2004; 12: 269-76.
- Kahan A, Uebelhart D, De Vathaire F. Long - term effects of chondroitins 4 and 6 sulfateon knee osteoarthritis: The study on osteoarthritis progression prevention, a twoyear, randomized, double - blind, placebo - controlled trial. Arthr Rheum 2009; 60 (2): 524-33.
- Hochberg M.C, Martel-Pelletier J, Monfort J et al. MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double - blind, non - inferiority trial versus celecoxib. Ann Rheum Dis 2016; 75 (1): 37-44.
- Fransen M, Agaliotis M, Nairn L et al. Glucosamine and chondroitin for knee placebo - controlled clinical trial evaluating osteoarthritis: a double - blind randomizedsingle and combination regimens. Ann Rheum Dis 2015; 74 (5): 851-8.
- Martel-Pelletier J, Roubille C, Abram F et al. First - line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis 2015; 74 (3): 547-56.
- Raynauld J.P, Pelletier J.P, Abram F et al. Long - Term Effects of Glucosamine and Chondroitin Sulfate on the Progression of Structural Changes in Knee Osteoarthritis: Six - Year Followup Data From the Osteoarthritis Initiative. Arthritis Care Res (Hoboken) 2016; 68 (10): 1560-6.
- Алексеева Л.И., Чичасова Н.В., Мендель О.И. и др. Рациональный выбор базисной терапии при остеоартрозе. Результаты открытого рандомизированного многоцентрового исследования препарата АРТРА® в России. РМЖ. 2005; 24: 1637-40.
- Светлова М.С. Эффективность препарата «Артра» в лечении остеоартроза (ОА). Научно - практич. ревматология. 2006; 2: 109.
- Родионова С.С., Еськин Н.А. комбинация хондроитина сульфата и глюкозамина (препарат Артра) для купирования боли и снижении потребления нестероидных противовоспалительных препаратов у пациентов с I-II стадиями остеоартроза коленных суставов. Хирургия. Журнал им. Н.И.Пирогова. 2016; 1: 67-72.
- Майко О.Ю., Савелова Е.Е. Клиническая эффективность хондроитин сульфата и его комбинации с глюкозамина гидрохлоридом при лечении гонартроза и коксартроза в условиях поликлиники. Клиническая геронтология. 2016; 22 (5-6): 18-25.
Supplementary files
